Pantoprazole Sodium

Proton Pump Inhibitor (PPI) Substituted Benzimidazole

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.5-1 mg/kg q24h Duration: 2-4 weeks for ulcers; may be longer for chronic conditions
Notes: Administer on an empty stomach, at least 1 hour before feeding. For IV use, 0.5-1 mg/kg once daily.
Cat PO 0.5-1 mg/kg q24h Duration: 2-4 weeks
Notes: Oral bioavailability is lower; consider higher end of dose. Administer on an empty stomach.
Horse PO 1-2 mg/kg q24h Duration: 4-6 weeks for EGUS; may be longer
Notes: Administer before feeding. For foals, dose may be adjusted.
Cattle IV 0.5-1 mg/kg q24h Duration: 3-5 days
Notes: Limited data; use with caution. Oral absorption is poor in ruminants.
Small Ruminants (sheep/goats) IV 0.5-1 mg/kg q24h Duration: 3-5 days
Notes: Limited data; use with caution.
Rabbit PO 0.5-1 mg/kg q24h Duration: 2-4 weeks
Notes: Limited data; use with caution. May be compounded.
Bird (Psittacines) PO 1-2 mg/kg q24h Duration: 2-4 weeks
Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications
  • Treatment and prevention of gastric ulcers
  • Management of gastroesophageal reflux disease
  • Reduction of gastric acid secretion in conditions where acid suppression is beneficial
Dog (Canine)
  • Gastric ulcers (including those induced by NSAIDs)
  • Esophagitis and gastroesophageal reflux disease (GERD)
  • Helicobacter pylori infection (as part of combination therapy)
  • Mast cell tumor (as adjunctive therapy to reduce histamine-induced gastric acid secretion)
  • Prevention of stress ulcers in critically ill patients
  • Zollinger-Ellison syndrome (rare)
Cat (Feline)
  • Gastric ulcers
  • Esophagitis and GERD
  • Chronic kidney disease (to reduce gastric acid and phosphate binders' efficacy? Actually, it is used to manage uremic gastritis)
  • Mast cell tumor (adjunctive therapy)
  • Helicobacter infection (less common)
Horse (Equine)
  • Gastric ulcers (Equine Gastric Ulcer Syndrome, EGUS)
  • Prevention of NSAID-induced gastric ulcers
  • Esophagitis
Cattle (Bovine)
  • Abomasal ulcers
  • Gastrointestinal bleeding (supportive therapy)
Small Ruminants (Sheep / Goat)
  • Abomasal ulcers (rarely used)
Rabbit & Small Mammals
  • Gastric ulcers (secondary to stress or NSAIDs)
  • Gastric stasis (as adjunctive therapy to reduce acid)
Avian & Poultry
  • Gastric ulcers (in some exotic birds, off-label use)
Exotic & Other Species
  • Reptiles: Gastric ulcers (limited data)
  • Small mammals (ferrets, guinea pigs): Gastric ulcers (off-label use)

Pharmacology & Mechanism of Action

Drug Class: Proton Pump Inhibitor (PPI) | Pharmacological Group: Substituted Benzimidazole

Mechanism of Action: Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells. It is a weak base that accumulates in the acidic environment of the parietal cell canaliculus, where it undergoes conversion to the active sulfenamide form. This active form covalently binds to cysteine residues of the proton pump, irreversibly inactivating it. Because the H+/K+-ATPase is the final step in acid secretion, pantoprazole effectively blocks both basal and stimulated gastric acid secretion, regardless of the stimulus (e.g., histamine, acetylcholine, gastrin). The antisecretory effect lasts longer than the plasma half-life due to the irreversible binding and the need for new pump protein synthesis.

Pharmacodynamics: Pantoprazole produces a dose-dependent inhibition of gastric acid secretion. In humans, a single oral dose of 40 mg reduces intragastric acidity by about 80% within 24 hours, with maximal effect after 2-4 days of repeated dosing. In veterinary species, similar effects are expected, but the duration and magnitude vary. The drug also has a mild anti-Helicobacter effect and may increase serum gastrin levels due to hypochlorhydria. It does not affect gastric emptying or lower esophageal sphincter pressure. The onset of action is slower than that of H2 antagonists, but the duration is longer, allowing once-daily dosing in most species.

⚡ Pharmacokinetics Summary

Absorption: Pantoprazole is well absorbed after oral administration, but its bioavailability is reduced by food. In dogs, the oral bioavailability is approximately 77% when fasted, but it decreases to about 40% when given with food. In cats, oral bioavailability is lower, around 50%, and also affected by food. The drug is acid-labile, so oral formulations are enteric-coated to prevent degradation in the stomach. Peak plasma concentrations occur 1-3 hours after oral administration in dogs and cats. Intravenous administration provides immediate and complete bioavailability.
Distribution: Pantoprazole has a volume of distribution of approximately 0.15-0.3 L/kg in dogs and cats. It is extensively bound to plasma proteins (about 98% in humans, but in dogs it is about 90%). It distributes into gastric mucosa and other tissues, but penetration into the central nervous system is minimal. It crosses the placenta and is excreted in milk in small amounts.
Metabolism: Pantoprazole is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system, specifically CYP2C19 and CYP3A4 in humans. In dogs, the major metabolic pathway is via CYP2C21 and CYP3A12. The metabolites are inactive and are excreted in urine and feces. There is some enterohepatic recirculation.
Excretion: The metabolites of pantoprazole are primarily excreted in the urine (about 80%) and the remainder in feces. In dogs, the elimination half-life is approximately 1-2 hours, but the pharmacodynamic effect lasts much longer due to irreversible binding to the proton pump. In cats, the half-life is slightly longer, around 2-3 hours. Renal excretion is the major route, so dose adjustment may be needed in severe renal impairment.
Half-Life: Dog: 1-2 hours; Cat: 2-3 hours; Horse: approximately 1.5 hours; Cattle: approximately 1 hour.
Bioavailability: Oral: Dogs ~77% (fasted), Cats ~50% (fasted); reduced by food. IV: 100%.
Protein Binding: Approximately 90% in dogs, 95% in cats, and 98% in humans.

Available Formulations & Strengths

Enteric-coated tablet 20 mg, 40 mg (PO)
Injectable solution 40 mg/vial (as sodium salt) (IV)
Oral suspension (compounded) Various (e.g., 5 mg/mL) (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to pantoprazole or other proton pump inhibitors
  • Use in patients with severe hepatic impairment (caution)
  • Do not use in patients with a history of drug-induced interstitial nephritis
  • Concurrent use with atazanavir or nelfinavir (protease inhibitors) is contraindicated due to reduced absorption
Warnings & Clinical Precautions:
  • Long-term use may lead to hypomagnesemia, vitamin B12 deficiency, and increased risk of fractures (in humans; monitor in animals).
  • May increase risk of bacterial gastroenteritis (e.g., Salmonella, Campylobacter) due to reduced gastric acidity.
  • Use with caution in animals with renal impairment; dose adjustment may be needed.
  • In horses, prolonged use may alter hindgut flora; monitor for diarrhea.
  • In cats, long-term use may cause hypergastrinemia and gastric polyps (rare).
  • Do not crush or break enteric-coated tablets; administer whole.
  • If given via nasogastric tube, use the oral suspension formulation.
  • May interfere with diagnostic tests for Helicobacter pylori (stop treatment 2 weeks before testing).

Adverse Effects & Reactions

Common:

  • Vomiting
  • Diarrhea
  • Flatulence
  • Abdominal pain
  • Anorexia
  • Headache (in humans; not observed in animals)

Serious / Severe:

  • Interstitial nephritis (rare)
  • Hepatotoxicity (rare)
  • Hypomagnesemia (with prolonged use)
  • Vitamin B12 deficiency (with prolonged use)
  • Increased risk of gastric polyps (in cats, rare)
  • Clostridioides difficile infection (in humans; potential in animals)

Rare:

  • Skin rash
  • Pruritus
  • Dizziness
  • Leukopenia
  • Thrombocytopenia
  • Gynecomastia (in humans; not reported in animals)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Ketoconazole, Itraconazole Reduced absorption of azole antifungals due to increased gastric pH. Moderate
Ampicillin esters Reduced absorption of ampicillin due to increased gastric pH. Moderate
Iron salts Reduced absorption of iron due to increased gastric pH. Mild
Digoxin Potential increased digoxin absorption; monitor digoxin levels. Mild
Warfarin Potential increased anticoagulant effect; monitor coagulation parameters. Moderate
Methotrexate Potential increased methotrexate levels due to reduced renal clearance; monitor for toxicity. High
Clopidogrel Reduced activation of clopidogrel to its active metabolite, decreasing antiplatelet effect (in humans; relevance in animals uncertain). Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Drowsiness
  • Confusion (in humans; not observed in animals)
  • Tachycardia

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Induce vomiting if ingestion is recent and the animal is conscious. Administer activated charcoal to reduce absorption. Monitor vital signs and provide fluid therapy as needed. In severe cases, manage electrolyte imbalances (e.g., hypokalemia, hypomagnesemia). Most overdoses are benign and resolve with supportive care.

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days🥚 Eggs: 0 days

Pantoprazole is not approved for food animals in many countries. If used off-label in food animals, follow local regulations and consult FARAD (Food Animal Residue Avoidance Databank) for specific withdrawal times. In the US, no withdrawal times are established; a conservative withdrawal period of at least 7 days for meat and 72 hours for milk is often recommended, but this is not official.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Protect from moisture. Keep in original container. Injectable solution should be stored at room temperature and protected from light; after reconstitution, use immediately or store for up to 24 hours at room temperature.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use. Veterinary use is extra-label.

Extra-Label (Off-Label) Use: In the US, pantoprazole is not FDA-approved for veterinary use; it is used extra-label under the Animal Medicinal Drug Use Clarification Act (AMDUCA). Extra-label use is permitted by or on the order of a licensed veterinarian within a valid veterinarian-client-patient relationship. For food animals, extra-label use is prohibited if there is an approved animal drug product that is labeled for the condition and contains the same active ingredient, unless the veterinarian determines it is not effective or causes adverse reactions. Withdrawal times must be followed as per FARAD recommendations.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pantoprazole is a potent proton pump inhibitor used in veterinary medicine for the management of gastric ulcers, esophagitis, and other acid-related disorders. It is generally well-tolerated, but its oral bioavailability is variable and affected by food; therefore, it should be administered on an empty stomach. In dogs and cats, the typical dose is 0.5-1 mg/kg once daily, but some patients may require twice-daily dosing for severe conditions. In horses, it is an effective treatment for EGUS, but it is more expensive than other PPIs like omeprazole. For animals that cannot take oral medications, the IV formulation is available. Long-term use should be avoided if possible due to potential adverse effects such as hypomagnesemia and vitamin B12 deficiency. Monitoring of serum magnesium and vitamin B12 levels is recommended for animals on chronic therapy. Drug interactions should be considered, especially with drugs that require an acidic environment for absorption. In food animals, use is limited due to lack of withdrawal data and poor oral bioavailability in ruminants. Overall, pantoprazole is a valuable option for acid suppression when other PPIs are not available or are ineffective.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)